Compare MPV & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | LCTX |
|---|---|---|
| Founded | 1988 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 391.1M |
| IPO Year | N/A | 1996 |
| Metric | MPV | LCTX |
|---|---|---|
| Price | $17.38 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 12.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $55.75 |
| Revenue Next Year | N/A | $2.96 |
| P/E Ratio | $10.15 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $15.65 | $0.37 |
| 52 Week High | $21.00 | $2.09 |
| Indicator | MPV | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 42.94 |
| Support Level | $15.86 | $1.44 |
| Resistance Level | $19.60 | $1.84 |
| Average True Range (ATR) | 0.76 | 0.08 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 42.00 | 51.48 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.